» Articles » PMID: 17640082

Increase in Nuclease Resistance and Incorporation of NF-kappaB Decoy Oligodeoxynucleotides by Modification of the 3'-terminus

Overview
Journal J Gene Med
Date 2007 Jul 21
PMID 17640082
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: For the development of molecular therapy based on oligodeoxynucleotides (ODN), ODN have to be stable against nucleases and be specific to the target transcription factor. To decrease non-specific binding and degradation from the 3'-terminus of ODN, we designed partially annealed ODN by binding the extremities of two single strands, resulting in a ribbon-shaped ODN, so called ribbon-type decoy ODN (R-ODN).

Methods: We evaluated the efficiency in the process of enzymatic ligation of R-ODN, the binding activity to nuclear factor-kappaB (NF-kappaB), and the stability against Exonuclease III and nucleases present in serum. The functional activity of R-ODN to inhibit NF-kappaB in vitro was evaluated in human aortic smooth muscle cells (VSMC): TNF-alpha-induced proliferation rate and MMP-9 expression were assessed after R-ODN transfection.

Results And Conclusions: Although R-ODN have a phosphodiester backbone, their physical conformation was designed to provide nuclease resistance without interfering with their binding activity. As expected, R-ODN showed more resistance to exonucleases and stability in 100% serum than non-modified decoy ODN (N-ODN). Importantly, the R-ODN construction did not interfere with its binding activity to NF-kappaB, similar to N-ODN. Transfection of R-ODN significantly inhibited the expression of MMP-9 induced by TNF-alpha in VSMC as assessed by real-time polymerase chain reaction (PCR), and R-ODN also inhibited the proliferation of VSMC induced by TNF-alpha (10 ng/ml), similar to phosphorothioate decoy ODN. Overall, the development of ribbon NF-kappaB decoy ODN could provide a useful tool for basic and clinical research.

Citing Articles

DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer.

Casas G, Perche F, Midoux P, Pichon C, Malinge J Mol Ther Nucleic Acids. 2022; 29:162-175.

PMID: 35847174 PMC: 9263874. DOI: 10.1016/j.omtn.2022.06.012.


REST/NRSF drives homeostatic plasticity of inhibitory synapses in a target-dependent fashion.

Prestigio C, Ferrante D, Marte A, Romei A, Lignani G, Onofri F Elife. 2021; 10.

PMID: 34855580 PMC: 8639147. DOI: 10.7554/eLife.69058.


Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis.

Mahjoubin-Tehran M, Teng Y, Jalili A, Aghaee-Bakhtiari S, Markin A, Sahebkar A Int J Mol Sci. 2021; 22(9).

PMID: 33922585 PMC: 8122884. DOI: 10.3390/ijms22094420.


DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD.

Klingler C, Ashley J, Shi K, Stiefvater A, Kyba M, Sinnreich M FASEB J. 2020; 34(3):4573-4590.

PMID: 32020675 PMC: 7079142. DOI: 10.1096/fj.201902696.


Molecular Pharmacological Approaches for Treating Abdominal Aortic Aneurysm.

Miyake T, Miyake T, Kurashiki T, Morishita R Ann Vasc Dis. 2019; 12(2):137-146.

PMID: 31275464 PMC: 6600097. DOI: 10.3400/avd.ra.18-00076.